# Soleno Therapeutics, Inc. (SLNO) Stock Analysis: A Biotech Contender with 184% Upside Potential

- Link: https://www.directorstalkinterviews.com/soleno-therapeutics-inc-slno-stock-analysis-a-biotech-contender-with-184-upside-potential/4121241210
- Published: 2026-02-23T11:34:10+00:00
- Author: Madison Wilson

Investors in the healthcare sector might want to keep a close eye on Soleno Therapeutics,
Inc. (NASDAQ: SLNO), a biotechnology company whose stock currently presents a significant
potential upside. With a market capitalization of $2.11 billion, Soleno is dedicated
to developing innovative treatments for rare diseases, a niche that continues to
attract substantial interest and investment.

The company’s flagship product, Diazoxide Choline Extended-Release tablets, is in
Phase III clinical trials for treating Prader-Willi Syndrome, a rare genetic disorder
that affects many aspects of a patient’s life. This focus on rare diseases could
be a strategic advantage, given the often streamlined regulatory paths and premium
pricing potential associated with orphan drug designations.

Despite a current stock price of $39.36, Soleno’s shares have seen better days, 
with a 52-week range stretching from $37.24 to $88.49. The stock is presently hovering
near its lower range, but analysts remain optimistic about its potential. The average
target price for SLNO is set at an impressive $111.92, reflecting a potential upside
of 184.36%. Such a figure is likely to capture the interest of growth-oriented investors
looking for substantial returns.

Analyst sentiment is overwhelmingly positive, with 13 buy ratings and no hold or
sell recommendations. This bullish outlook is supported by a target price range 
extending from $60.00 to $145.00. These figures indicate a strong belief in the 
company’s growth prospects and the eventual success of its clinical endeavors.

Financially, Soleno faces some challenges typical of a clinical-stage biopharmaceutical
company. The company reports an earnings per share (EPS) of -1.75 and a return on
equity (ROE) of -20.66%, highlighting the ongoing costs associated with drug development.
Additionally, its free cash flow stands at -$5.7 million, which could be a concern
for some investors, particularly those focused on near-term profitability.

From a technical perspective, Soleno’s stock shows signs of potential volatility.
The 50-day moving average is $44.11, while the 200-day moving average is higher 
at $63.12, suggesting the stock has been under some pressure in recent months. The
relative strength index (RSI) of 63.34 indicates that the stock is approaching overbought
territory, which investors might want to monitor closely.

While Soleno does not currently offer a dividend, its focus remains on leveraging
its clinical advancements to drive future growth. The absence of a payout ratio 
further emphasizes the company’s commitment to reinvesting in its core research 
and development activities.

In summary, Soleno Therapeutics, Inc. presents a compelling case for investors willing
to embrace the risks and rewards of the biotechnology sector. With a promising product
pipeline, strong analyst support, and significant upside potential, SLNO could be
an attractive addition to a diversified portfolio focused on high-growth opportunities
within the healthcare industry. As always, potential investors should conduct their
due diligence and consider their risk tolerance when evaluating such stocks.

Share on:
